Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses

摘要: The objective of this work was to assess the effect interferon beta-1a (Avonex) on rate development clinically definite multiple sclerosis and brain magnetic resonance imaging changes in subgroups based type presenting event, baseline parameters, demographic factors Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) trial. After onset a first demyelinating 383 patients with evidence subclinical demyelination were treated corticosteroids randomly assigned receive weekly intramuscular injections 30 microg or placebo. treatment within assessed proportional hazards models both for combined outcome >1 new enlarging T2 lesions imaging. A beneficial noted all evaluated. Adjusted ratios optic neuritis, brainstem-cerebellar, spinal cord syndrome 0.58 (p = 0.05), 0.40 0.03), 0.30 0.01) sclerosis/magnetic 0.50 < 0.001), 0.41 0.004), respectively. benefit measures also seen gender, age. Interferon is when initiated at clinical event demyelination. present brainstem-cerebellar syndromes, syndromes.